Intezyne, Inc

Intezyne offers a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT™ Method to limit chemotherapeutics’ anti-tumor activity to within the tumor itself, thereby sparing healthy tissues. To date, the IVECT Method has shown positive preclinical efficacy and safety profiles in multiple cancer models versus best-in-class chemotherapeutic agents. Ultimately, the IVECT Method has demonstrated preclinical proof-of-concept in a number of therapeutic and diagnostic categories, giving the Company the opportunity to monetize this asset through licensing agreements outside of Intezyne’s primary oncology focus.